DV
Dividend Vision

STRO — Sutro Biopharma

Sutro Biopharma (STRO)

Total return is -86.5% over the past 7.9 years, 286.8 points behind SPY at 200.3%. Its deepest 1-year drawdown was 47.9%.

Sutro Biopharma is an oncology company that develops antibody drug conjugates (ADCs) and vaccine candidates using proprietary protein synthesis and site-specific conjugation platforms. The company's pipeline includes STRO-004 for solid tumors, STRO-003 targeting ROR1 for various cancers, and pneumococcal vaccine candidates in clinical trials, along with partnerships for development and commercialization with companies including Ipsen and Astellas Pharma. The company does not currently distribute dividends and is oriented toward clinical-stage drug development rather than income generation.

STRO key facts

Asset type
Stock
Asset class
Equity
Inception date
09/27/2018
Last close
$20.48
Market cap
$374,326,208
Average volume
448752.0
Beta
1.52
Payout ratio
0.0
Forward P/E
10.0301
EPS
$-15.62